NCT07383025

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan

Conditions

• Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

Type	Name	Description
DRUG	Mavacamten	According to the product label

Timeline

• Start date: 2025-05-21
• Primary completion: 2029-11-30
• Completion: 2029-11-30
• First posted: 2026-02-03
• Last updated: 2026-02-03

Locations

1 site across 1 country: Japan

Regulatory

• FDA-regulated drug study